DaVita is expected to report Q3 2026 revenue of $3.41 billion and earnings of $3.78 per share, with the stock currently trading at $165.45 against an average analyst target of $178.20. Investors are primarily focused on U.S. dialysis treatment volume growth as the primary indicator of organic patient base expansion.
Recent performance has been supported by improved clinical labor productivity and favorable reimbursement rate updates. Analysts are looking for confirmation that these operational efficiencies can continue to offset inflationary pressures and shifts in the healthcare regulatory environment.